Congress hands pharma a $2B tax break for brain research—no price controls attached
H.R. 2085 — Mental Health Research Accelerator Act of 2025 · Filed by Mike Thompson (D-CA) · 7 cosponsors · Introduced Mar 11, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new federal tax credit worth up to $2 billion per year (2027–2030) for companies and research institutions conducting translational research on neurodegenerative diseases and psychiatric conditions. The credit covers 25% of qualifying research expenses, with allocation decisions made by the Secretary of the Treasury in consultation with HHS, FDA, and NIH based on scientific merit. Tax-exempt entities (universities, nonprofits, government agencies) can transfer their credit to for-profit partners, allowing private companies to claim the tax benefit even when the research is conducted by public institutions.
Why we flagged it
Despite the public-health framing, the bill's core mechanism is a $2 billion annual tax credit that flows primarily to for-profit pharmaceutical and biotech companies. The credit is structured as a business tax incentive, not a direct public research investment or price guarantee.
What the text implies
- Tax-exempt entity credit transfer mechanism allows universities and nonprofits to conduct research at public expense, then transfer the tax benefit to private companies—effectively subsidizing private R&D with public research infrastructure and tax revenue.
- No requirement that treatments developed under this credit be affordable, available to the public, or priced reasonably—companies can use the subsidy to offset R&D costs while charging monopoly prices.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical companies (Pfizer, Bristol Myers Squibb, Johnson & Johnson); biotech firms; medical device manufacturers